CN107076758B - 作为心力衰竭预后标志物的脑啡肽酶 - Google Patents

作为心力衰竭预后标志物的脑啡肽酶 Download PDF

Info

Publication number
CN107076758B
CN107076758B CN201580050585.0A CN201580050585A CN107076758B CN 107076758 B CN107076758 B CN 107076758B CN 201580050585 A CN201580050585 A CN 201580050585A CN 107076758 B CN107076758 B CN 107076758B
Authority
CN
China
Prior art keywords
nep
leu
asn
soluble
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580050585.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN107076758A (zh
Inventor
A·贝斯·格尼斯
J·卢蓬·罗斯
A·加兰·奥尔特加
J·巴拉利亚特·马丁内斯·德奥萨巴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP
Original Assignee
Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP filed Critical Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP
Publication of CN107076758A publication Critical patent/CN107076758A/zh
Application granted granted Critical
Publication of CN107076758B publication Critical patent/CN107076758B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96497—Enkephalinase (3.4.24.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CN201580050585.0A 2014-08-29 2015-08-14 作为心力衰竭预后标志物的脑啡肽酶 Expired - Fee Related CN107076758B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14182846.7 2014-08-29
EP14182846.7A EP2990800A1 (en) 2014-08-29 2014-08-29 Neprilysin as heartfailure (HF) prognostic marker
PCT/EP2015/068729 WO2016030209A1 (en) 2014-08-29 2015-08-14 Neprilysin as heart failure prognostic marker

Publications (2)

Publication Number Publication Date
CN107076758A CN107076758A (zh) 2017-08-18
CN107076758B true CN107076758B (zh) 2019-10-22

Family

ID=51421966

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580050585.0A Expired - Fee Related CN107076758B (zh) 2014-08-29 2015-08-14 作为心力衰竭预后标志物的脑啡肽酶

Country Status (11)

Country Link
US (1) US10203341B2 (https=)
EP (2) EP2990800A1 (https=)
JP (1) JP6661216B2 (https=)
CN (1) CN107076758B (https=)
AU (1) AU2015309112A1 (https=)
CA (1) CA2959094A1 (https=)
ES (1) ES2734876T3 (https=)
MX (1) MX2017002453A (https=)
RU (1) RU2017109086A (https=)
SG (1) SG11201701393YA (https=)
WO (1) WO2016030209A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7510649B2 (ja) 2019-11-06 2024-07-04 国立大学法人 香川大学 心不全マーカー

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102869786A (zh) * 2010-02-24 2013-01-09 巴塞罗那自治大学 用于诊断路易体痴呆的遗传标记
WO2013153177A1 (en) * 2012-04-12 2013-10-17 B.R.A.H.M.S Gmbh Prognosis of adverse events in patients with suspected chronic heart failure
CN103403554A (zh) * 2011-02-03 2013-11-20 雅培制药有限公司 慢性心力衰竭的预后和诊断方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565994A (en) * 2001-09-03 2010-02-26 Intreat Pty Ltd Antibodies to non-functional P2X7 receptor, diagnosis and treatment of cancers and other conditions
AU2010315008B2 (en) * 2009-11-07 2015-12-03 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2879550T3 (es) * 2012-08-24 2021-11-22 Novartis Ag Inhibidores de epn para tratar enfermedades caracterizadas por la dilatación o remodelación auriculares.
US20140206632A1 (en) 2013-01-22 2014-07-24 Singulex, Inc. Endothelin in the Diagnosis of Cardiac Disease
US9102635B2 (en) * 2013-02-14 2015-08-11 Novartis Ag Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
CU24330B1 (es) * 2013-02-14 2018-03-13 Novartis Ag Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102869786A (zh) * 2010-02-24 2013-01-09 巴塞罗那自治大学 用于诊断路易体痴呆的遗传标记
CN103403554A (zh) * 2011-02-03 2013-11-20 雅培制药有限公司 慢性心力衰竭的预后和诊断方法
WO2013153177A1 (en) * 2012-04-12 2013-10-17 B.R.A.H.M.S Gmbh Prognosis of adverse events in patients with suspected chronic heart failure

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure;M.Wegner et al.;《Cardiovascular Research》;19961231;第31卷 *

Also Published As

Publication number Publication date
ES2734876T3 (es) 2019-12-12
EP3186639B1 (en) 2019-03-20
JP6661216B2 (ja) 2020-03-11
CA2959094A1 (en) 2016-03-03
RU2017109086A3 (https=) 2019-03-06
WO2016030209A1 (en) 2016-03-03
JP2017526924A (ja) 2017-09-14
US20170254815A1 (en) 2017-09-07
US10203341B2 (en) 2019-02-12
EP2990800A1 (en) 2016-03-02
MX2017002453A (es) 2017-10-23
AU2015309112A1 (en) 2017-04-06
SG11201701393YA (en) 2017-03-30
CN107076758A (zh) 2017-08-18
RU2017109086A (ru) 2018-10-01
EP3186639A1 (en) 2017-07-05

Similar Documents

Publication Publication Date Title
Sturgeon et al. Analytical error and interference in immunoassay: minimizing risk
Wu et al. Analytical and assay issues for use of cardiac troponin testing for risk stratification in primary care
CN109564225B (zh) 作为指示不良事件的标志物的组蛋白和/或proADM
Meijers et al. The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure
CN105556308B (zh) 用于阑尾炎的诊断和预后及腹痛病因的区分的方法和组合物
US11307209B2 (en) Method diagnosis of a prenatal disorder by selective determination of placental growth factor 2
EP3710831A1 (en) Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (nash) and advanced liver fibrosis
Potocki et al. Copeptin and risk stratification in patients with acute dyspnea
Nigro et al. BNP but Not s-cTnln is associated with cardioembolic aetiology and predicts short and long term prognosis after cerebrovascular events
Motiwala et al. Concentrations of highly sensitive cardiac troponin-I predict poor cardiovascular outcomes and adverse remodeling in chronic heart failure
KR20170072215A (ko) 생물마커 및 예측 방법
CN103562725B (zh) 川崎病的诊断标志物和治疗靶点
CN107667294A (zh) 用于预测慢性肾病发生风险的方法
Liu et al. Methodological evaluation and comparison of five urinary albumin measurements
EA034364B1 (ru) Иммуноанализ для обнаружения хромогранина а
CN107076758B (zh) 作为心力衰竭预后标志物的脑啡肽酶
Kloska et al. Reference values and biological determinants for cardiac myosin-binding protein C concentrations assessed with an enzyme-linked immunosorbent assay
KR20100127210A (ko) 비특이적 질환용 일반 마커로서의 ｙｋｌ-40
EP3311164B1 (en) Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
US20160123995A1 (en) Biomarker of Rehospitalization After Heart Failure
KR20190019919A (ko) 일반 집단에서 lvh 로의 진행자 확인을 위한 가용성 st2
Soosaipillai et al. Macrotroponin interference and association with cardiotoxicity in patients receiving cardiotoxic breast cancer therapy: a pilot study
US20190250172A1 (en) Prognosis of adverse outcomes by determination of midkine levels after cardiovascular stress
Class et al. Patent application title: Biomarker of Rehospitalization After Heart Failure Inventors: Philippe Rouet (Toulouse Cedex 4, FR) Fatima Smith-Rouet (Toulouse Cedex 4, FR) Franck Desmoulin (Toulouse Cedex 4, FR) Michel Galinier (Toulouse Cedex 4, FR)
HK1193650A (en) Diagnostic markers and therapeutic targets of kawasaki disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20191022

Termination date: 20200814

CF01 Termination of patent right due to non-payment of annual fee